CERAMOPTEC INDUSTRIES, INC. Patent applications |
Patent application number | Title | Published |
20130041357 | CLASS 1 LASER TREATMENT SYSTEM - Eye-safe, low-power-density, Class 1 or Class 3R laser treatment systems for medical applications are disclosed. Systems having controlled power and stray irradiation can meet laser safety requirements according to IEC 60825-1:2007 or equivalent for eye-safe rating; classification as laser-Class 1 or as laser-Class 3R. Laser system comprises a diode laser source, an optical fiber probe, means for detecting and identifying said optical probe and means to ensure that laser power transmitted from the fiber probe is limited to pre-specified maximum power level per application; laser wavelength; emission characteristics; probe characteristics; limiting values according to applied safety regulations. Device can identify the connected optical fiber probe to exclude using non-conforming optical fiber probes and/or to limit maximum output to optical powers in compliance with laser safety regulations. System preferably operates at a wavelength of 1400 nm or higher. Breakage or leakage from fiber probe is detectable and prevented. | 02-14-2013 |
20130041307 | APPLICATION OF BETA-FUNCTIONALIZED DIHYDROXY-CHLORINS FOR PDT - The present invention provides methods to obtain biologically active compounds that can be used as photosensitizers for diagnostic and therapeutic applications, particularly for PDT of cancer, infections and other hyperproliferative diseases, fluorescence diagnosis and PDT treatment of a non-tumorous indication such as arthritis, inflammatory diseases, viral or bacterial infections, dermatological, ophthalmological or urological disorders. An embodiment of the present invention consists of a method to synthesize diketo-chlorins as precursors. In yet another embodiment these precursors are converted to β-functionalized hydroxy- and dihydroxy-chlorins. Another embodiment is to provide amphiphilic compounds with a higher membrane affinity and increased PDT-efficacy. Another embodiment consists of the formulation of the desired isomer into a liposomal formulation to be injected avoiding undesirable effects like precipitation at the injection site or delayed pharmacokinetics of the tetrapyrrole systems. | 02-14-2013 |
20130035684 | Laser Treatment of Tissues at Wavelengths above 1330 nm - A medical laser system is disclosed for ablation/resection/coagulation of unwanted tissue, including parenchymal lung resection to facilitate/accelerate growth/wound healing. System comprises laser energy sources and conveying means, optical fiber. A diode laser source emits above 1330 nm, at least 50 Watts, through an optical fiber onto target tissue. Wavelength, 1340 nm is preferred. Wavelength ranges 1330-1390 nm and 1450-1550 nm, are also useful. Additionally a wavelength, between 800-1100 nm, can be used. Wavelength differences maximize beam quality. Two radiation sources emit simultaneously from fiber's distal end. One emits at ˜1320 nm and the other emits at ˜1340 nm or ˜1360 nm with maximum total output power of 60 W or larger. Preferably, the ratio of the power levels is fixed at 1:1.5 and output power is the sum of individual lasers. High beam quality and power density system combines emissions from a diode laser and a fiber laser. | 02-07-2013 |
20120263625 | GLYCO-SUBSTITUTED DIHYDROXY-CHLORINS AND -FUNCTIONALIZED CHLORINS FOR ANTI-MICROBIAL PHOTODYNAMIC THERAPY - Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided. The key to these conjugates is connecting dihydroxychlorins or β-functionalized chlorins to carbohydrate moieties. These conjugates are found to be very effective in combating bacterial infections caused by Gram-positive and Gram-negative bacteria, including their resistant strains. Significantly, they are also effective in complex environments, including blood, serum, and other body fluids which are present in patient's body. A method of use to control pathogenic microorganisms in human and animals is also provided. | 10-18-2012 |
20110034854 | PDT ASSISTED VISION CORRECTION AND SCAR PREVENTION - A method and formulation are disclosed for improving the results of corneal refractive surgery, and generally reducing post-operative scarring and scarring arising from other traumas. In the vision examples, after completion of a procedure, including Photorefractive Keratotomy (PRK) or Laser-In-Situ Keratomileusis (LASIK), a photosensitizer or photosensitizer precursor is applied to the treatment site. After allowing sufficient time for the photosensitizers to accumulate among proliferating cells that occur as a result of ablation, radiation appropriate to activate the photosensitizers is administered to the treatment site. The photosensitizer is thus activated to destroy only those proliferating cells. In this way, proliferating tissue is eliminated and the cornea maintains the shape created during the surgery. As a result, instances of regression and the need for follow-up treatments, is minimized. This method is also useful for preventing post-surgical scarring that can lead to vision problems such as corneal haze. Likewise the method and formulations, presented here, are suitable for reducing post-operative scarring, and trauma cased scarring in general. For such scars, a photosensitizer or photosensitizer precursor is topically applied to the treatment site. After allowing sufficient time for the photosensitizers to attach to proliferating cells, radiation appropriate to activate the photosensitizers is administered to the treatment site. The photosensitizer is activated to destroy only those proliferating cells. | 02-10-2011 |
20100179523 | Urological Diode Laser Systems having a Glass-Fiber Application System - The invention relates to a system for medicinal treatment, in particular for treating benign prostatic hyperplasia BPH, for use in the event of tumor resection or for use in thoracic surgery. The system comprises a diode laser device for producing a laser beam and to an application system based on optical wave guides that can be endoscopically introduced into a patient. Said system is designed in such a manner that the laser beam, produced by the diode laser device is guided through the application system and is emitted by said application system so that biological tissue can be treated in a selective manner with the emerging laser beam. | 07-15-2010 |